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Dimerization or oligomerization of G protein-coupled receptors (GPCRs) are known to mod-
ulate receptor functions in terms of ontogeny, ligand-oriented regulation, pharmacological
diversity, signal transduction, and internalization. Class B GPCRs are receptors to a family
of hormones including secretin, growth hormone-releasing hormone, vasoactive intesti-
nal polypeptide and parathyroid hormone, among others. The functional implications of
receptor dimerization have extensively been studied in class A GPCRs, while less is known
regarding its function in class B GPCRs. This article reviews receptor oligomerization in
terms of the early evidence and current understanding particularly of class B GPCRs.
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INTRODUCTION
G protein-coupled receptors (GPCRs) comprise the largest subset
of cell surface receptors which transduce signals via coupling to
heterotrimeric G proteins and are extensively involved in the fine-
tuning of physiological processes. They constitute at least 3% of
the human genome and have great pathophysiological importance
with an abundance of information indicating their dysfunction to
be associated with diseases such as diabetes, visual disability, and
chronic inflammation. As a result, at least 30–40% of pharmaceu-
tical drugs developed are targeted at GPCRs. Traditionally, GPCRs
were recognized to elicit physiological responses via coupling as
monomeric units to G proteins in a 1:1 stoichiometric ratio. How-
ever there is now a growing body of evidence confirming that
GPCRs can self-associate or associate with different receptors to
formhomo-and/or hetero-oligomers.With thewealth of informa-
tion recently discovered, oligomerization has been implicated to
play important roles in maturation, cell surface delivery, signaling,
and internalization of GPCRs. The concept of oligomerization is
groundbreaking as it not only widens our perspective in under-
standing the molecular determinants to receptor regulation and
function, but also provides new opportunities in the development
of personalized drug treatments. In recent years, the small 15-
member class B [secretin (SCT) or class II] GPCRs are emerging
as oligomerization candidates with efforts contributed predomi-
nantly by Laurence Miller’s and Dominik Schelshorn’s groups. In
this article, we will provide an overview of the history of oligomer-
ization and review the available information on class BGPCRs and
its functional implications.
EARLY EVIDENCE OF GPCR DIMERIZATION BY
PHARMACOLOGICAL AND BIOCHEMICAL APPROACHES
Although GPCR oligomerization is now a widely accepted phe-
nomenon with modern non-radiative techniques such as res-
onance energy transfer (RET) strategies that are effective in
demonstrating homo- and/or hetero-oligomer interactions, early
clues to their existence were often indirect and overlooked. In
1975, a binding experiment of a potent antagonist to β2-adrenergic
receptors (ADRB2) in frog erythrocyte membranes led to find-
ings of negative cooperativity among binding sites (Limbird
et al., 1975; Limbird and Lefkowitz, 1976). This was pioneer-
ing evidence for oligomerization and can be better explained as
site–site interactions amongst ADRB2 oligomers based on today’s
knowledge. Soon after, radiation inactivation, cross-linking and
co-immunoprecipitation studies have also provided biochemical
evidence complementing earlier observations of oligomeriza-
tion. For example, immunoaffinity chromatography and sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
showed the subunit molecular weight of mammalian lung ADRB2
to be 59 kDa, while radiation inactivation of ADRB2 resulted in
a functional subunit molecular weight of 109 kDa (Fraser and
Venter, 1982). Taken together, the contrasting molecular sizes
indicate that ADRB2s exist in the membrane as dimers of two
subunits (Fraser and Venter, 1982). Similar suggestions have also
been made for the rat liver membrane α1-adrenergic receptor
(ADRA1; Venter et al., 1984) and human platelet α2-adrenergic
receptor (ADRA2; Venter et al., 1983) which each have molecu-
lar masses of 160 kDa. Alternatively, cross-linking experiments,
using photoaffinity labeling reagents, cell permeable cross-linkers,
agonists, and antagonists (Capponi and Catt, 1980; Paglin and
Jamieson, 1982; Guillemette and Escher, 1983; Rogers, 1984;
Carson et al., 1987; Rondeau et al., 1990; Siemens et al., 1991)
have been used to study the dimeric nature of angiotensin II
(ANGII) receptors. Using similar methods, other GPCRs such
as the dopamine D2 (Ng et al., 1996), calcium-sensing (Bai et al.,
1998), and chemokine (Rodriguez-Frade et al., 1999) receptors
have also beendemonstrated to exist as dimeric units. Other exper-
iments such as photoaffinity labeling of MRs from various brain
regions and the heart have also provided evidence for the presence
of inter convertible dimers and tetramers (Avissar et al., 1983).
The idea of higher order oligomerizationwas further supported by
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comparable findings of thyrotropin hormone receptor complexes
(Gennick et al., 1987).
In the 1990s, another line of evidence demonstrating GPCR
oligomerization stemmed from trans-complementation, and
dominant-negative and -positive effect studies on co-expression of
chimeric and mutant receptor constructs. One of the first exper-
iments of these series was performed in 1993 by co-expression of
chimeric muscarinic and adrenergic receptors composed of their
C-terminal units (Maggio et al., 1993). Although no binding activ-
ity was detected when the chimeras were expressed individually,
co-expression restored ligand binding to a level comparable to
wild-type receptors and allowed agonist-dependent phospholipase
C (PLC) activation (Maggio et al., 1993). These observations were
explained as molecular interaction of the chimeras restoring func-
tionality in a heteromeric complex (Maggio et al., 1993). Other
trans-complementation studies for GPCRs such as theANGII type
1a (AGTR1a; Monnot et al., 1996), somatostatin (SST – SST1
and SST5; Rocheville et al., 2000) and dopamine (D2 and D3;
Scarselli et al., 2001) receptors have also provided useful infor-
mation in support of GPCR oligomerization. This concept was
further explored in experiments showing dominant-negative or
-positive effects such those observed with the antidiureticV2 vaso-
pressin (Zhu and Wess, 1998) and ADRB2 (Hebert et al., 1998),
respectively. Although there are reports of different functional
effects, the various studies described are useful in offering more
clues to molecular interactions amongst GPCRs.
Though earlier experiments provided a large pool of informa-
tion suggesting GPCR oligomerization, there was still no direct
evidence to support this concept. Early western blot studies
often showed presence of immuno-reactive bands with molec-
ular masses two or more times greater than a single receptor
(Harrison and van der Graaf, 2006). Western blot was later
performed in combination with immunoprecipitation using anti-
bodies to endogenous or epitope tagged-receptors, providing for
the first time direct evidence of GPCR interaction. Using this tech-
nique, homodimerization of ADRB2 (Hebert et al., 1996) was
demonstrated. For example, cross-species oligomerization was
also detected in select serotonin receptors with lysophosphatidic
acid receptors 1 and3 andγ-aminobutyric acidB2 receptors (Salim
et al., 2002), dopamine D1 and D2 receptors (Lee et al., 2004), and
α1b and β2 adrenergic receptors (Uberti et al., 2005).
RET APPROACH IN GPCR OLIGOMERIZATION
Since the days of radioactive inactivation experiments, the concept
of GPCR oligomerization has been confirmed with emergence of
biophysical data providing more in-depth evidence. In the last
decade, RET techniques have gained popularity and are one of the
best resolution strategies developed for direct study of GPCR inter-
actions. The basis of these techniques lies in non-radiative energy
transfer from an excited “donor” molecule to an “acceptor” (Wu
and Brand, 1994). Bioluminescence RET (BRET) and fluorescence
RET (FRET) are two of the most widely used RET approaches.
BRET relies on a naturally occurring biophysical process inmarine
species between a luminescent donor and fluorescent acceptor,
while only fluorescent molecules are utilized in FRET (Wu and
Brand, 1994). These have provided advantages over traditional
biochemical methods including high signal to noise ratios, use
of intact cells, precise targeting of fusion receptors and actual
quantification of the proportion and type of GPCR oligomers
formed, and therefore are currently the most commonly used
methods. Based on these approaches, a wide range of GPCRs
have since been identified to function as oligomers, including
the yeast α-factor (Overton and Blumer, 2000), dopamine D2
(Wurch et al., 2001), thyrotropin (Latif et al., 2001, 2002), opi-
oid (Ramsay et al., 2002), neuropeptide Y (Dinger et al., 2003),
melatonin (Ayoub et al., 2004), adrenergic (Mercier et al., 2002;
Ramsay et al., 2002; Carrillo et al., 2004), and chemokine (Percher-
ancier et al., 2005) receptors. Despite the successes in identifying
various oligomers, there are several drawbacks of the BRET and
FRET techniques.With regards to these aforementionedRET tech-
niques, a primary concern is that the signals generated cannot be
used to discriminate between non-mature and mature proteins
within the various cellular locations (e.g., intracellular complexes
and plasma membrane; Gandia et al., 2008; Cottet et al., 2011).
Therefore, the information provided is essentially limited and
more steps may be needed to address this concern. Moreover,
another drawback of BRET and FRET is potential bleed-through
artifacts which may be due to spectral overlaps, substrate insta-
bility, and auto-luminescence from serum containing medium,
which together skew the interpretation of the results (Pfleger et al.,
2006; Gandia et al., 2008). Therefore, the careful use of appropri-
ate controls and fluorescent molecules need to be considered when
using these RET techniques for the study of oligomerization. More
recently, homogeneous time-resolved fluorescence (HTRF) which
combines FRET with time-resolved measurements has also been
considered. HTRF provides the advantage of increasing assay sen-
sitivity and accuracy via replacing donormoleculeswith rare-earth
lanthanides (e.g., europium cryptate) whose properties include
non-auto-fluorescence and long emissionhalf-lives (Degorce et al.,
2009). Using HTRF, a number of receptors have been identified
to dimerize, e.g., GABA (Maurel et al., 2004) and metabotropic
glutamate-like receptors (Rondard et al., 2006; Brock et al., 2007)
and oligomerize, e.g., dopamine D2 (Guo et al., 2008) and his-
tamine H4 (Albizu et al., 2006) receptors. Fluorescence life-time
imagingmicroscopy (FLIM) is also useful in overcoming the draw-
backof theuse of intact cells andbleed-through inBRETandFRET
assays. Moreover, FLIM can also provide useful information on
the proportion of non-dimerizing and dimerizing partners and
also visual images indicating where the signals are localized, for
example the dimerization of the transcription factor CCAAT and
enhancer binding protein-α in livemouse pituitary cell nuclei (Sun
et al., 2011).
OLIGOMERIZATION OF CLASS B GPCRs
Although techniques in studying oligomerization have existed for
more than three decades, information with regards to the class B
GPCRs is still in its infancy and largely contributed by the newer
RET techniques. In class A GPCRs, several important interfaces
including the transmembrane (TM) domains have been identified
to contribute toward oligomerization. Moreover, oligomerization
has also been shown toplay a role inmodulating function, via alter-
ing parameters such as ligand binding, signaling, and trafficking.
Though the SCT receptor (SCTR) remains to be the most exten-
sively studied class B GPCR, information regarding other class B
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GPCRs continues to grow. Collectively, the SCT superfamily of
hormones and receptors represent important drug targets due to
their physiological roles in glucose homeostasis, feeding behav-
ior, and vascular contractility. They are characterized by a large
N-terminal extracellular domain (ECD) containing six cysteine
residues for disulfide bond formation and N-glycosylation sites
for receptor conformation and ligand binding. The N-terminal
ectodomain is linked to seven hydrophobic TM domains arranged
inα-helical bundles connected by three exoloops, three endoloops,
and a short cytosolic C-terminus (Miller et al., 2007). Currently,
there are intense efforts to link the various structural domains
to oligomerization in hopes of unraveling the specific molecu-
lar determinants that may affect certain pathological conditions.
Taken together, information regarding the oligomerization of class
B GPCRs will be highly valuable in enhancing the specificity of
future drug design.
SECRETIN RECEPTORS
The SCTR was first cloned from the rat in 1991 (Ishihara et al.,
1991) and is now recognized as one of the most extensively stud-
ied class B GPCRs, and the first that was demonstrated to have the
ability to form oligomers. By investigating wild-type and exon-3
splice variants using confocal imaging and BRET, SCTR has been
shown to be capable of homo- and heterodimerization (Ding et al.,
2002a,b; Tables 1 and 2). When expressed alone, the exon-3 splice
variant receptors lack SCT binding and signaling activity but are
able to traffic normally to the cell surface. However, co-expression
of the variant with the wild-type SCT results in a dominant-
negative effect, indicating direct physical interaction. Since the
variant receptor is predominantly expressed, comprising up to
70% of SCTRs in gastrinoma, over the wild-type receptor, het-
erodimerization has been suggested to be an underlying factor in
facilitating tumor growth through its dominant-negative effects.
Table 1 | Homodimerization of class B GPCRs.
Homodimer Technique Key domain Reference
SCTR/SCTR Morphological FRET
BRET
GxxxG motif independent
Lipid-exposedTM4 residues
(human: Gly243, Ile247)
Ding et al. (2002a), Harikumar et al. (2006, 2007,
2008a), Lisenbee and Miller (2006)
GCGR/GCGR BRET n/a Roed et al. (2012), Schelshorn et al. (2012)
GLP1R/GLP1R BRET n/a Schelshorn et al. (2012), Whitaker et al. (2012)
GLP2R/GLP2R BRET n/a Schelshorn et al. (2012)
GIPR/GIPR BRET n/a Schelshorn et al. (2012), Whitaker et al. (2012)
VIPR1/ VIPR1 Immunohistochemistry
Co-immunoprecipitation
Morphological FRET
BRET
n/a Harikumar et al. (2006)
VIPR2/VIPR2 Morphological FRET
BRET
n/a Harikumar et al. (2006)
ADCYAP1R1/ADCYAP1R1 Time-resolved FRET n/a Maurel et al. (2008)
GHRHR/GHRHR Co-immunoprecipitation McElvaine and Mayo (2006)
PTHR1/PTHR1 Crystallography
FRET
BRET
ECD α-helix (human: Ile135, Arg179,
Val183, Leu187)
Pioszak et al. (2010)
CALCR/CALCR Co-immunoprecipitation
FRET
BRET
Lipid-exposedTM4 residues
(human: Arg236, Val250, Thr253)
C-terminal tail
Seck et al. (2003), Harikumar et al. (2010)
CALCRL/CALCRL Co-immunoprecipitation
FRET
BRET
n/a Heroux et al. (2007)
CRHR1/CRHR1 FRET
BRET
Pseudo signal peptide (based on rat
CRHR2a: Asn13 prevents oligomerization)
Kraetke et al. (2005), Young et al. (2007), Teich-
mann et al. (2012)
Techniques used for study and domains indicated to be important are described. SCTR, secretin receptor; GCGR, glucagon receptor; GLP1R, glucagon-like peptide 1
receptor; GLP2R, glucagon-like peptide 2 receptor; GIPR, glucose-dependent insulinotropic polypeptide receptor; VIPR1, vasoactive intestinal peptide (VIP) receptor
1; VIPR2, VIP receptor 2; ADCYAP1R1, PACAP type 1 receptor; GHRHR, growth hormone-releasing hormone receptor; PTHR1, parathyroid hormone receptor type 1;
CALCR, calcitonin receptor; CALCRL, CALCR-like receptor; CRHR, corticotropin-releasing hormone receptor; FRET, fluorescence resonance energy transfer; BRET,
bioluminescence resonance energy transfer; n/a, information not available.
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Table 2 | Heterodimerization of class B GPCRs.
Heterodimer Technique Key
domain
Reference
SCTR/GLP1R BRET n/a Harikumar et al. (2008b)
SCTR/GLP2R BRET n/a Harikumar et al. (2008b)
SCTR/VIPR1 Morphological FRET
BRET
n/a Harikumar et al. (2006,
2008b)
SCTR/VIPR2 Morphological FRET
BRET
n/a Harikumar et al. (2006,
2008b)
SCTR/GHRHR BRET n/a Harikumar et al. (2008b)
SCTR/PTHR1 BRET n/a Harikumar et al. (2008b)
SCTR/PTHR2 BRET n/a Harikumar et al. (2008b)
SCTR/CALCRL BRET n/a Harikumar et al. (2008b)
GCGR/GLP1R BRET n/a Roed et al. (2012),
Schelshorn et al. (2012)
GCGR/GLP2R BRET n/a Schelshorn et al. (2012)
GCGR/GIPR BRET n/a Schelshorn et al. (2012)
GLP1R/GIPR BRET n/a Schelshorn et al. (2012),
Whitaker et al. (2012)
GLP2R/GIPR BRET n/a Schelshorn et al. (2012)
VIPR1/VIPR2 Co-immunoprecipitation
BRET
n/a Harikumar et al. (2006)
Techniques used for study are described.
This study in 2002 was a breakthrough for class B GPCRs, showing
the first physiological relevance of class B GPCR oligomerization.
Taken together with data from subsequent studies, SCTR homod-
imerization is now recognized to occur, independent of ligand
binding (Ding et al., 2002a; Harikumar et al., 2006).
To decipher the molecular determinants of oligomerization,
receptors with mutated N- and C- terminal domains were studied
(Lisenbee and Miller, 2006). Mutant receptors, as expected, were
unable to bind SCT or sort efficiently to the plasma membrane,
but the ability to still produce BRET signals above background
suggested that the TM spanning core alone was sufficient for
oligomerization (Lisenbee and Miller, 2006). Moreover, SCTR
dimerization was also found to be independent of the GxxxG
helix–helix motif (Lisenbee and Miller, 2006), which is essen-
tial for oligomerization of class A receptors, such as the yeast
α-factor (Overton et al., 2003) and β2 adrenergic (Salahpour et al.,
2004) receptors. In addition, FRET signals within organelles of the
receptor biosynthetic pathway including the endoplasmic reticu-
lum, Golgi clusters, and plasma membrane were also detected,
suggesting the occurrence of oligomerization even during the
maturation of nascent molecules (Lisenbee and Miller, 2006). To
further explore the domains responsible for homodimerization,
TM peptide competition experiments have been performed. Of
the seven TM peptides applied, TM4 was the only segment that
disrupted BRET signals, suggesting it to be a functionally impor-
tant interface for oligomerization (Harikumar et al., 2007). Using
alanine mutagenesis, the contribution of TM4 in SCTR oligomers
was pinpointed to two lipid-facing residues: Gly243 and Ile247
(Harikumar et al., 2007). Although no direct pathophysiological
connection has been made regarding these new data, reduced
signaling of monomeric forms suggests that SCTR dimers are
necessary in optimizing functionality (Harikumar et al., 2007).
Most recently, bimolecular luminescence complementation and
BRET experiments have clarified SCTR’s existence as homodimers
and not higher order oligomers (Harikumar et al., 2008a). There-
fore, previous references to oligomerization of SCTRs should be
referred to as homodimerization unless otherwise stated. Aside
from homodimers, SCTRs have also been implicated to form
heterodimers with a wide range of class B GPCRs, including
the glucagon-like peptide 1 receptor (GLP1R), glucagon-like pep-
tide 2 receptor (GLP2R), vasoactive intestinal peptide receptor 1
(VIPR1), vasoactive intestinal peptide receptor 2 (VIPR2), growth
hormone-releasing hormone receptor (GHRHR), parathyroid
hormone 1 receptor (PTHR1), parathyroid hormone 2 recep-
tor (PTHR2), and calcitonin receptor-like (CALCRL; Harikumar
et al., 2006, 2008b; Table 2).
GCG, GLP1, GLP2, AND GIP RECEPTORS
Receptors for glucagon (GCG), glucagon-like peptide 1 (GLP1),
glucagon-like peptide 2 (GLP2), and glucose-independent
insulinotropic polypeptide (GIP) are well-known regulators of
carbohydrate, fat, and protein metabolism. Oligomerization
within the GCG subfamily of receptors was recently identified but
with some controversy (Roed et al., 2012; Schelshorn et al., 2012).
Homodimerizationof eachGCG family receptormemberhas been
reported through BRET experiments (Schelshorn et al., 2012),
however, these events remained unconfirmed with the lack of
appropriate negative controls and the fact that another group was
unable to repeat some of these results (Roed et al., 2012). Amongst
the receptors, theGCG receptor (GCGR) andGIP receptor (GIPR)
exhibited the strongest ability to homodimerize but BRET signals
were slightly reduced upon application of GCG or GIP, while the
GLP receptors were weakly responsive and unaffected by agonist
stimulation (Schelshorn et al., 2012). Further studies with BRET
saturation experiments confirmed GLP1R and GIPR homodimer-
ization, with some agonist-induced reduction (Schelshorn et al.,
2012). On the basis of these results, it was suggested that ligand
binding leads to a decrease in affinity and conformational change
of the homodimers (Schelshorn et al., 2012). In a similar study,
the same BRET saturation results were obtained for the GLP1R,
however no changes were observed when GLP1 was added (Roed
et al., 2012). This was similarly the case for GCGRs (Roed et al.,
2012). Taken together, it is highly likely that the GCG subfamily
receptors are able to form homodimers (Table 1), while further
studies with appropriate use of controls are necessary to solidify
this conclusion.
Despite the controversy, heterodimerization of GLP1R and
GIPR has been confirmed by BRET saturation and kinetic exper-
iments (Roed et al., 2012; Schelshorn et al., 2012; Whitaker et al.,
2012; Table 2). The heterodimerization event between GLP1R and
GIPR was found to be dose-dependently induced by GLP1 and
inhibited by GIP (Schelshorn et al., 2012). Further application of
GLP1 and its antagonists to this system showed heterodimeriza-
tion to occur independently to GLP1R activation, but was induced
by ligand binding,with BRET signals reaching amaximum10–30 s
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after addition of GLP1 (Schelshorn et al., 2012). More specifically,
the heterodimers were suggested to play a role in allosteric modu-
lation with arrestin recruitment. In basal conditions, GLP1R and
GIPR are proposed to exist mainly as monomers or homodimers,
GLP1, under low concentrations (<30 nM), acts as a high affinity
ligand for functioning of GLP1R but switches to become a low
affinity ligand to GIPR with high concentrations (>30 nM). This
promotes formation of heterodimers with altered G protein cou-
pling resulting in GIP-like activity that can later be dissociated
in the presence of GIP (Schelshorn et al., 2012). Heterodimer-
ization of GLP1R and GIPR was also confirmed by a later study
with wild-type GLP1R rescuing mutant GIPR function (Whitaker
et al., 2012).
VIP/PACAP RECEPTORS
To elicit physiological response, vasoactive intestinal peptide (VIP)
and pituitary adenylate cyclase activating polypeptide (PACAP)
bind to three receptors, namely VIPR1, VIPR2, and PACAP
receptor type 1 (ADCYAP1R1). Discoveries of VIPR1 and VIPR2
homodimers were made during the study of SCTR oligomeriza-
tion in 2006 (Harikumar et al., 2006; Table 1). These physical
interactions were demonstrated by BRET experiments and found
to be modulated by agonist but not antagonist binding (Hariku-
mar et al., 2006). In the same study, BRET results also indicated
that VIPR1 and VIPR2 to form hetero-oligomers and VIP bind-
ing was found to affect this association negatively (Harikumar
et al., 2006; Table 2). Formation of these oligomeric complexeswas
also supported by co-immunoprecipitation studies (Langer et al.,
2006). Besides formation of hetero-oligomers between the two
subtypes, both VIPRs can oligomerize with SCTR. Interestingly,
co-expression of SCTR with either VIPR resulted in strong intra-
cellular FRET signals, suggesting the trapping of hetero-oligomers
within organelles of the biosynthetic pathway (Harikumar et al.,
2006). Since this retention occurred independent to SCT and VIP
stimulation, it has been described as a regulatory step, allowing
SCTR to have dominant-negative effects by inhibitingVIP’s action
on cells expressing both receptors (Harikumar et al., 2006).Within
a physiological context, the SCT and VIPR are often co-expressed;
therefore information regarding their physical interactions may
provide some insights toward diseases such as pancreatic carci-
noma (Estival et al., 1981; Ding et al., 2002a). Of the receptor trio,
information regardingADCYAP1R1oligomerization is scarcewith
only one study indicating its homodimerization by time-resolved
FRET studies (Maurel et al., 2008; Table 1).
GROWTH HORMONE-RELEASING HORMONE RECEPTORS
Growth hormone-releasing hormone (GHRH) is a hypothalamic
peptide responsible for stimulating growth hormone release and
disruption of the peptide–receptor pair often results in abnor-
mal growth, such as dwarfism or gigantism. GHRHRs have been
suggested to form oligomers, with co-expression of mutant and
wild-type receptors having dominant-negative effects (McElvaine
and Mayo, 2006). The physical interaction amongst GHRHRs
was implied with the reduction of ligand binding ability and
cyclic adenosine monophosphate (cAMP) production to 60% in
presence of truncated receptors (McElvaine and Mayo, 2006).
These observations were further supported by detection of both
receptor forms by differentially tagged co-immunoprecipitation
studies (McElvaine and Mayo, 2006). The relevance of these find-
ings has been hypothesized in the context of pituitary adenomas
for example, with preferential expression of the mutant receptor
down-regulating signaling and thus modulating growth hormone
release (Matsuno et al., 1999).
PARATHYROID HORMONE RECEPTORS
Parathyroid hormone receptors (PTHRs) play an important role
in calcium homeostasis and bone maintenance, mediating the
effects of its natural ligands parathyroid hormone (PTH) and
PTH-related protein (PTHrP). In 2008 and 2009, the crystal struc-
tures of PTH and PTHrP bound human PTHR1 were determined
by engineering the receptor as a readily crystallizing maltose bind-
ing protein (Pioszak and Xu, 2008; Pioszak et al., 2009). A“hot dog
bun” three-layer α-β-βα fold structure was described, forming the
central hydrophobic groove within which the ligands in an amphi-
pathic helical fashion docked (Pioszak and Xu, 2008; Pioszak et al.,
2009). More importantly, the crystal structures depicted ligand
binding to PTHR1 ECD monomers in a 1:1 stoichiometric ratio
(Pioszak and Xu, 2008; Pioszak et al., 2009). Interestingly a year
later, the crystal structure of ligand-free PTHR1 showed the ECDs
as dimers (Pioszak et al., 2010). These ECD dimers were formed in
a similar fashion to ligand-bound PTHR1, with the C-terminal of
one ECD forming α-helices to occupy the peptide-binding groove
of the other (Pioszak et al., 2010). Besides crystallography, BRET
and FRET experiments also supported existence of these ECD-
mediated PTHR1 homodimers (Pioszak et al., 2010). To confirm
the ligand-independent nature of ECD dimerization shown by
the crystal structures, PTH was applied to PTHR1s in BRET
studies and as predicted, led to agonist-induced dissociation of
the PTHR1 homodimers (Pioszak et al., 2010). Furthermore, co-
expression of mutant and wild-type ECD PTHR1s showed that
monomeric units of the PTHR1 were sufficient for functional-
ity (Pioszak et al., 2010). With the discovery of monomeric and
dimeric units of PTHR1, this may be useful in understanding how
the two biologically distinct peptides PTH and PTHrP are able to
modulate function through binding to the same receptor (Pioszak
et al., 2010).
CALCITONIN AND CORTICOTROPIN-RELEASING HORMONE
RECEPTORS
Targeting mainly osteoblasts, calcitonin is important in calcium
homeostasis and has anorexic and analgesic effects in the central
nervous system. In a study focused on rabbit calcitonin receptors
(CALCRs), homo- and heterodimers of the alternatively spliced
CALCR (Δe13) and CALCR type 1a isoform (CALCR1a) were
detected by co-immunoprecipitation and FRET analyses (Seck
et al., 2003). Co-expression resulted in a dominant-negative effect
of the splice variant Δe13 over CALCR1a, resulting in reduced
CALCR1a surface expression, cAMP response, and extracellu-
lar signal-regulated kinase (ERK) phosphorylation (Seck et al.,
2003). The combined data highlight the importance of CALCR1a
homodimers in proper expression and functioning, and also sug-
gest a role of Δe13 in regulating CALCR1a expression (Seck
et al., 2003). In contrast, both static and saturation BRET studies
on the human CALCR were found unable to form homodimers
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(Harikumar et al., 2010). On the basis of SCTR studies where TM4
was identified to be an important interface (Harikumar et al.,
2007), the same TM was also considered for CALCR (Harikumar
et al., 2010). Comparing human and rabbit TM4 domains, only
one single amino acid was found to differ between the two species,
namelyArg and His at position 236, respectively (Harikumar et al.,
2010). Synthetic TM4 peptides were constructed by exchange
of these identified lipid-facing residues to those from respective
CALCR species and human SCTR, and their application enhanced
human CALCR BRET signals (Harikumar et al., 2010). Similar to
the SCTR, lipid-exposed residues in TM4 are also key in facilitat-
ing homodimerization events in humanCALCR (Harikumar et al.,
2010). Though not studied in-depth, the closely related CALCRL
has also been demonstrated to exist as homodimers (Heroux and
Bouvie, 2005).
Within the class BGPCRs, the corticotropin-releasing hormone
receptors (CRHRs) are the least studied. CRHRs are mediators
of stress response, modulating the release of adrenocorticotropic
hormone from the anterior pituitary. Two subtypes of the recep-
tors exist, but only subtype 1 (CRHR1) has been studied for
oligomerization. Data from FRET and co-immunoprecipitation
studies show evidence of CRHR1 forming constitutive homod-
imers independent to ligand binding but their physiological
relevance remains unexplored (Kraetke et al., 2005; Young et al.,
2007).
FUNCTIONAL CONSEQUENCES OF OLIGOMERIZATION IN
CLASS B GPCRs
Within the large superfamily of cell surface proteins, obligatory
oligomerization is unique only to class C GPCRs and recognized
as a prerequisite for activation and allosteric modulation (Kniaz-
eff et al., 2011; Chun et al., 2012). However, in the case of class A
and B GPCRs where oligomerization has also been established as a
real event, the implications on their functions remain unresolved.
This is further complicated by the fact that monomeric GPCRs
are demonstrated to be independently capable of regulating sig-
nal transduction via a series of processes including the activation
of G proteins (White et al., 2007; Whorton et al., 2007, 2008;
Kuszak et al., 2009), kinase phosphorylation and signal “switch-
off” by arrestin binding (Xu et al., 1997; Bayburt et al., 2011).
To decipher the underlying functional significance, the effect of
GPCR oligomerization on various functional properties needs to
be examined with emphasis on class B GPCRs, as examples.
LIGAND BINDING
Ligand binding, either with an agonist or antagonist, is funda-
mental in activating subsequent downstream signaling cascades.
Natural ligands for the class B GPCRs share common features,
comprising of 25 or more amino acids and have diffuse phar-
macophoric domains (Ulrich et al., 1998). Critical residues have
been identified throughout the length of the peptides (Dong et al.,
2011), with the N-terminus recognized as necessary for receptor
binding and signaling, whilst the C-terminus contributes mainly
to high affinity binding and receptor specificity. Crystallography
(Sasaki et al., 1975; Parthier et al., 2007) and nuclear magnetic
resonance (NMR; Grace et al., 2007; Venneti and Hewage, 2011)
analyses have also been useful, elucidating the class B ligands
to preferentially assume an α-helical conformation particularly
in their C-terminal regions. Structure–activity studies have fur-
ther implicated the specific interaction of ligand–receptor regions,
with the C-terminal ligand domain first fitting into the recep-
tor ECD peptide-binding cleft, thus facilitating the N-terminal
ligand domain to associate with the receptor core helical bun-
dle domain (Dong et al., 2004, 2008; Mann et al., 2007; Parthier
et al., 2009). Though the molecular interactions described are
on the basis of monomeric GPCRs, similar associations may be
expected from oligomeric forms. Similarly, molecular modeling
and crystallization studies have predicted the binding pockets in
SCTR and PTHR homodimers, respectively, to be localized in the
extracellular N-terminal domains (Gao et al., 2009; Pioszak et al.,
2010). Moreover, the SCTR homodimer peptide-binding clefts
are demonstrated to reside opposite to the dimerization interfaces
that may allow structural freedom for each protomer to bind to
its respective ligand in a 1:1 stoichiometric ratio, as expected for
monomeric GPCRs (Gao et al., 2009). Though limited, the two
models show oligomerization to have minimal structural mod-
ifications in terms of adequately exposing the binding pockets,
allowing ligand–receptor interactions in class B GPCRs.
In majority of studies for this receptor class, the use of pep-
tide or mutant receptors to inhibit dimerization events have been
utilized to explore the contribution of such receptor interactions
toward functionality. On thebasis of these studies, oligomerization
has been demonstrated to have differential effects on the ligand
binding affinity of class B GPCRs. Using TM4 peptides that are
known to disrupt SCTR homodimerization, both monomeric and
dimeric SCTR forms were found to have analogous ligand bind-
ing properties (Harikumar et al., 2007). Similarly, oligomerization
was also found to have null effects on the ligand binding affinity of
PTHR1, with the non-dimerizing R179A/V183A double mutant
maintaining wild-type PTH binding activity (Pioszak et al., 2010).
In another study, CALCR mutants also bound calcitonin sat-
urably with no statistically significant differences in binding
affinity (Harikumar et al., 2010). In contrast, disruption of GLP1R
homodimerization by TM4 peptides resulted in elimination of
G protein-dependent high affinity binding to GLP1(7–36)NH2
(Harikumar et al., 2012). Moreover, co-expression of full-length
and truncated GHRHRs resulted in a decrease in GHRH ligand
binding and has been described to be resultant of the truncated
receptor inducing a dominant-negative effect, leading to confor-
mational changes which inhibit proper binding (McElvaine and
Mayo, 2006). Nevertheless, these contrasting findings are consis-
tent with recent reports of oligomerization having variable effects
on the kinetics and efficiencies amongst receptors (Dorsch et al.,
2009;Hern et al., 2010). Therefore, oligomerizationmay be impor-
tant in modulating receptor activity via altering ligand binding
affinity only in certain class B GPCRs.
ALLOSTERY
In recent studies, a link between oligomerization and allosteric
regulation has been established in class B GPCRs. Allostery con-
cerns association of a ligand or molecule to the receptor other than
its orthosteric site, modifying its functional properties in either
a positive or negative manner (May et al., 2007). Using a clas-
sical radio-ligand binding approach, the dissociation of labeled
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SCT in the absence or presence of unlabeled SCT was moni-
tored to study the negative binding cooperativity of SCTRs (Gao
et al., 2009). The wild-type dimerizing receptors were found to
shift from monophasic to biphasic dissociation upon presence of
unlabeled SCT peptide, whilst the non-dimerizing mutant recep-
tors maintained monophasic dissociation, regardless of treatment
(Gao et al., 2009). On the basis of these results, the homod-
imeric SCTRs have been speculated to predominantly exist in a
G protein-coupled high affinity state and the monomeric forms
in a G protein-uncoupled low affinity state (Gao et al., 2009).
Though the molecular basis responsible for the allosteric effects
are still unknown, steric hindrance by the two large extracellular
amino-terminal domain or selective coupling may be underly-
ing factors contributing to the negative cooperativity observed
in SCTRs (Miller et al., 2012). Similarly, the homodimerization
event amongst the GCGR and GLP1R have also been identified
to exhibit negative cooperativity with addition of labeled native
peptides to their respective receptors leading to accelerated dis-
sociation of unlabeled ligands (Roed et al., 2012). More recently,
the ECD of the GCGR has been demonstrated to act as a neg-
ative regulator of receptor activity through interaction with the
third extracellular loop (Koth et al., 2012), a region not only rec-
ognized to contribute to receptor affinity and efficacy, but may
also aid in optimizing the arrangement of the TM bundle for
efficient ligand binding (Peeters et al., 2011). As this case, agonist-
occupied homodimers may induce negative cooperativity through
structural modifications that affect ligand binding. Though the
molecular determinants remain to be confirmed, there is a clear
relation between dimerization and negative allostery. Aside from
the typical ligand-induced allostery, physical coupling of each pro-
tomer in a oligomeric complex may also play a role (Haack and
McCarty, 2011). Within the class B GPCRs, this has only been
demonstrated in heteromers of the GLP1R and GIPR,where GIPR
is suggested to act allosterically on the GLP1R to decrease maxi-
mal responses in calcium flux and β-arrestin recruitment assays
(Schelshorn et al., 2012). In a later study, mutant GIPR func-
tion rescue by wild-type GLP1R was observed, with reduction in
GLP1 responsiveness (Whitaker et al., 2012). Again GIPR may be
exerting an allosteric effect on GLP1R, but the precise molecular
basis needs to be explored with further structural and functional
studies.
EFFECTS OF AGONIST OCCUPATION
Besides allostery, agonist occupation of class B GPCRs can also
promote the association or dissociation of oligomeric complexes.
In contrast to SCT homodimers that are unaffected by ligand
binding (Ding et al., 2002a; Harikumar et al., 2006), GLP1 bind-
ing was found to encourage the dimerization between GLP1R
and GIPR (Schelshorn et al., 2012). A model proposed describes
GLP1 to act as a high affinity ligand for GLP1R at low con-
centrations, but also becomes a low affinity ligand for GIPR at
higher concentrations to trigger formation of the GLP1 and GIPR
dimer (Schelshorn et al., 2012). Interestingly, the presence of the
high affinity GIP reverses the GLP1 induced association, dis-
solving the heteromer to a monomeric state (Schelshorn et al.,
2012). As previously discussed, the GIPR has allosteric effects
on the GLP1R when heterodimerized. Taken together with the
agonist-induced association and/or dissociation of receptors, this
may be a mechanism by which the receptors activate their G pro-
teins and subsequent downstreamsignaling cascades (Gomes et al.,
2001). Agonist-induced dissociation has also been reported for the
PTHR1 via structural mimicry of PTH/PTHrP binding (Pioszak
et al., 2010), however the functional relevance remains unclear.
Other examples of agonist-induced disruption of oligomeriza-
tion include VIPR1 and VIPR2 homodimers and VIPR1/VIPR2
heterodimers (Harikumar et al., 2006).
SIGNALING
Another prominent effect of oligomerization in class B GPCRs is
on signaling selectivity and efficiency. In particular, cAMP and
PLC are two of the predominant pathways in which physiolog-
ical responses are elicited through in class B GPCRs. Therefore
most oligomerization studies have extended their focus beyond
information from ligand binding and BRET studies, but also rely
on the cAMP and calcium mobilization responses of receptors.
In particular, SCTRs are one of the first class B GPCRs demon-
strated to have altered functionality due to homodimerization. By
TM4 peptide competition studies, the disruption of SCTR dimer-
ization was found to result in impairment of the generation of
cAMP (Harikumar et al., 2007). The dimeric form of SCTR was,
therefore, suggested be the optimal conformation for G protein
activation (Harikumar et al., 2007). Similarly, disruption of the
GLP1R homodimers was found to not only affect cAMP for-
mation and ERK phosphorylation, but also lead to a complete
loss of intracellular calcium mobilization response (Harikumar
et al., 2012). In the case of GLP1R homodimers, signal transduc-
tion involves more than one G protein and/or accessory proteins
such as β-arrestins. Nonetheless, dimerization is likely the basis
in altering G protein coupling efficiency (Harikumar et al., 2012).
This was also evident in the heterodimerization of GLP1 and GIP
receptors, with the heteromer having more“GIP-like” (Schelshorn
et al., 2012) pharmacological characteristics. Based on most of the
studied class B GPCRs, oligomerization seems to exhibit a general
trend in affecting G protein activation and signaling efficiency.
However, oligomerization should not be a prerequisite for signal-
ing, as monomers such as the PTHRs have been demonstrated to
be capable of activating G proteins on their own (Pioszak et al.,
2010). Therefore, oligomerization is likely important in provid-
ing structural framework to facilitate G protein coupling and thus
modulate function.
TRAFFICKING
A number of studies have suggested the importance of oligomer-
ization in cellular trafficking of the receptors and is a process that
occurs early in the biosynthetic pathway (Bulenger et al., 2005).
Within the class B GPCRs, this aspect of oligomerization has
been most thoroughly explored for the SCTRs. Indeed using a
combination of fluorescence and morphologic FRET microscopy
studies, the SCTR homodimers were localized within organelles
of the biosynthetic pathway including the tubular endoplasmic
reticulum, Golgi clusters and the plasma membrane (Lisen-
bee and Miller, 2006). The homodimerization of SCTRs has
therefore been suggested to occur as early as newly synthesized
receptors and continue throughout their maturation process
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(Lisenbee and Miller, 2006). Moreover, non-dimerizing SCTR
constructs were not expressed nor yielded a significant mor-
phological FRET signal both intracellularly and on the plasma
membrane (Harikumar et al., 2007). Taken together, the SCTR
data support the idea that oligomerization may be necessary for
receptors to by-pass quality checkpoints before being delivered
to their site of action (Bulenger et al., 2005). Consistent with the
SCTR data, theVIPRs have also been identified in the biosynthetic
pathway andplasmamembrane as homo- andheterodimeric com-
plexes (Harikumar et al., 2006). Interestingly, heterodimerization
involving the SCTR and VIPR impaired trafficking to the plasma
membrane with morphological FRET analyses revealing these het-
eromers to be trappedwithin the biosynthetic pathway, lacking cell
surface expression (Harikumar et al., 2006). In the case of VIPRs,
heterodimerization with SCTR predominates over the homod-
imerization of VIPRs (Harikumar et al., 2006). This demonstrates
dominant-negative inhibition of oligomerization on cellular traf-
ficking, which may be useful for modulating function in cells
expressing both the SCTR and VIPR (Harikumar et al., 2006). In
a later study, a small amount of mutant GIPR completely lacking
N-glycosylation and cell surface expression was rescued by co-
expression with GLP1R but not GIPR, suggesting the possibility
of a heteromer which has a dominant-positive effect in facilitating
the trafficking of GIPR (Whitaker et al., 2012).
STRUCTURAL ELEMENTS GOVERNING OLIGOMERIZATION IN
CLASS B GPCRs
With the class B GPCRs key in a number of pathophysiological
diseases and mounting evidence indicating their oligomerization
to have influence in modulating various functional properties,
this has fueled research in unraveling the structural determi-
nants. To date, majority of studies have suggested the importance
of different domains in GPCR oligomerization. However within
the class B GPCRs, a common theme seems to prevail with
several lines of evidence indicating the TM domains to be impor-
tant. More specifically, it is the fourth TM domain, which has
been implicated as a key molecular domain in class B receptor
homodimerization (Table 1). This has been well documented
by the disruption of SCTR homodimerization by TM4 peptides,
with mutation studies identifying the lipid-facing residues namely
Gly243 and Ile247 as important interfaces (Harikumar et al., 2007).
Similarly, TM4 also provides the primary interface for GLP1R
homodimerization, as supported by experimental data with TM4
peptide treatment dissociating the complex (Harikumar et al.,
2012). Consistent with findings from the SCTR studies, lipid-
facing residues within TM4 of the CALCR were also found to
be necessary for dimerization (Harikumar et al., 2010). Though
TM4 has been indicated to provide basis for dimerization in
class B GPCRs, other domains including the ECD in PTHR
(Pioszak et al., 2010) and C-terminal tail in CALCR (Harikumar
et al., 2010) may also have some role. More recently, a pseudo
signal peptide unique to the CRHR2a was identified to inhibit
oligomerization (Teichmann et al., 2012). Steric hindrance by
the bulky nature of the high mannose glycan protruding from
this N-terminal domain has been suggested, thus preserving
CRHR2a as monomers (Teichmann et al., 2012). Current predic-
tion programs are unable to differentiate between canonical and
pseudo signal peptides, as a result the presence of similar struc-
tures may also exist in other class B GPCRs (Rutz et al., 2006;
Teichmann et al., 2012). Taken together, dimerization of class B
GPCRs may not necessarily be dependent solely on one structural
motif but instead is a highly complex interaction amongst several
domains to achieve optimal structural basis for the fine-tuning of
physiological processes.
FUTURE PERSPECTIVES
Over the last three decades, there has been a rapid development
of techniques for studying the molecular interaction between
GPCRs. Though early evidence was largely overlooked and lim-
ited to the class A GPCRS, establishment of RET techniques,
in particular, have led to reinterpretation and strongly supports
the concept of GPCR oligomerization. In recent years, class B
GPCRs are also gaining merit in their ability to form homo-
and hetero- oligomers, with the SCTRs being the most exten-
sively studied. Though still nascent, the information available
supports the role of dimerization in modulating function of
class B GPCRs. Naturally, ligand binding to a receptor results
in conformational changes in G protein arrangement to elicit
downstream signaling pathways. When GPCRs associate, con-
formational arrangements also occur to modulate functionality.
For example, SCTR homodimers have greater signaling responses
than its monomeric counterparts. Furthermore, GPCR dimeriza-
tion may also act as a repair mechanism, trans-complementing
domains to restore binding sites and thus signaling, as observed
for spliced SCTRs (Ding et al., 2002a,b). In terms of traffick-
ing, oligomerization may also play a role with evidence of SCTR
homodimers present as early as nascent molecules throughout
the biosynthetic pathway (Lisenbee and Miller, 2006). Though
seemingly simple when considering homodimeric units, evidence
of GPCR heterodimerization, for example of SCTRs with a wide
range of class B GPCRs, such as VIPR and GCGR, suggests a more
complex role. Attempts have also been made to link these physical
characteristics to pathophysiological responses in class B GPCRs,
for example, association of SCTR homodimers to gastrinoma
(Ding et al., 2002b) and GLP1R/GIPR heterodimers to diabetes
(Whitaker et al., 2012). GPCR oligomerization is therefore func-
tionally relevant and further research will be useful in providing
more insights in understanding the molecular determinants to in
vivo responses and for drug design.
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